Drugs / HS-10234
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04477096 | Aug → Sep 2020 | — | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03903796 | Aug 2018 → May 2020 | chronic hepatitis B virus infection | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10234 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04477096 ↗ |
| Action | Inhibit | “HS-10234, a novel prodrug of tenofovir (TFV), functions by inhibiting nucleotide reverse transcriptase against retroviral infections including hepatitis B virus and human...” PMID 34727366 ↗ Oct 2021 |
| Route | Oral | “HS-10234 25mg will administer orally once daily” NCT03903796 ↗ |